Chapman RH - Search Results

1

Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.

Joshi M, Atlas SJ, Beinfeld M, Chapman RH, Rind DM, Pearson SD, Touchette DR. Joshi M, et al. Among authors: chapman rh. Value Health. 2023 Jun;26(6):823-832. doi: 10.1016/j.jval.2022.12.005. Epub 2022 Dec 16. Value Health. 2023. PMID: 36529422 Free article.

2

New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?

Pearson SD, Ollendorf DA, Chapman RH. Pearson SD, et al. Among authors: chapman rh. Value Health. 2019 Jun;22(6):656-660. doi: 10.1016/j.jval.2019.01.012. Epub 2019 May 17. Value Health. 2019. PMID: 31198182 Free article.

3

Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets.

Chapman RH, Kumar VM, Whittington MD, Pearson SD. Chapman RH, et al. Value Health. 2021 Jun;24(6):839-845. doi: 10.1016/j.jval.2021.02.008. Epub 2021 May 10. Value Health. 2021. PMID: 34119082 Free article.

4

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.

Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Sandhu AT, et al. Among authors: chapman rh. Ann Intern Med. 2016 Nov 15;165(10):681-689. doi: 10.7326/M16-0057. Epub 2016 Aug 30. Ann Intern Med. 2016. PMID: 27571284

5

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.

Ollendorf DA, Chapman RH, Pearson SD. Ollendorf DA, et al. Among authors: chapman rh. Value Health. 2018 May;21(5):547-552. doi: 10.1016/j.jval.2018.01.008. Value Health. 2018. PMID: 29753351 Free article.

6

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease.

Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson J. Zimmermann M, et al. Among authors: chapman rh. Value Health. 2019 Feb;22(2):161-167. doi: 10.1016/j.jval.2018.09.2841. Epub 2018 Oct 25. Value Health. 2019. PMID: 30711060 Free article.

7

Author Reply.

Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson J. Zimmermann M, et al. Among authors: chapman rh. Value Health. 2019 Aug;22(8):972-973. doi: 10.1016/j.jval.2019.03.009. Epub 2019 Jul 22. Value Health. 2019. PMID: 31426939 Free article. No abstract available.

8

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.

Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA. Carlson JJ, et al. Among authors: chapman rh. Pharmacoeconomics. 2019 Nov;37(11):1321-1327. doi: 10.1007/s40273-019-00832-2. Pharmacoeconomics. 2019. PMID: 31485925 Free PMC article.

9

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.

Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Guzauskas GF, et al. Among authors: chapman rh. J Manag Care Spec Pharm. 2021 Apr;27(4):455-468. doi: 10.18553/jmcp.2021.27.4.455. J Manag Care Spec Pharm. 2021. PMID: 33769850 Free PMC article.

10

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Whittington MD, et al. Among authors: chapman rh. Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. doi: 10.1016/j.anai.2016.10.028. Epub 2016 Dec 4. Ann Allergy Asthma Immunol. 2017. PMID: 27923549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters